Palisade Bio presents PALI-2108 data at ACG 2026
The company presented clinical, pharmacokinetic, pharmacodynamic and mechanistic data on PALI-2108 in ulcerative colitis and Crohn’s disease.
Story updates
12:11:20 PM UTC
SquawkNews
Five presentations connect targeted intestinal exposure and sustained systemic drug exposure with PDE4 target engagement and early clinical activity, supporting ongoing Phase 2 developmentTwo presentations selected for ACG Presidential Poster Awards, a distinction received by approximately 5% of ac…
12:11:36 PM UTC
SquawkNews
Palisade Bio presented five ACG 2026 posters showing targeted intestinal exposure, PDE4 engagement, and early clinical activity for PALI-2108, supporting ongoing Phase 2 UC and Crohn’s programs; two abstracts received ACG Presidential Poster Awards.Material DetailsContext by AI AnalystThis is an ea…